Research and Markets: Sudan and South Sudan Pharmaceuticals and Healthcare Report Q2 2012
March 15 2012 - 1:18PM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/5a995a/sudan_and_south_su)
has announced the addition of the "Sudan and South Sudan
Pharmaceuticals and Healthcare Report Q2 2012 `" report to their
offering.
BMI maintains its view that the outlook for Sudan and South
Sudan's pharmaceutical markets will be more dependent on the
economic and political stability of the two countries, rather than
their need for medicines. With the most recent Sudanese civil war
ended in 2005 after more than 20 years of fighting, tension remains
high and violent clashes between forces in South Sudan and its
northern neighbour continue. It is clear that the market will not
be able to attract significant interest from multinational
companies for at least half a decade. Market pioneers are likely to
be non-Western, small generic drugmakers. Larger firms may be able
to increase their exposure to market with deals with local
distributors or sell bulk products that can be repackaged and sold
on. In the next few years, drug expenditure is likely to remain
erratic. Over the longer term, improved access to medicines and
demand for more advanced pharmaceuticals will remain at an elevated
growth rate.
Sudan and South Sudan Pharmaceuticals and Healthcare Report
provides industry professionals and strategists, corporate
analysts, pharmaceutical associations, government departments and
regulatory bodies with independent forecasts and competitive
intelligence on Sudan and South Sudan's pharmaceuticals and
healthcare industry.
Headline Expenditure Projections:
- Pharmaceuticals: SDG1.49bn (US$563mn) in 2011 to SDG1.68bn
(US$571mn) in 2012; +12.9% in local currency terms with a 1.4% in
US dollar terms. High in local currency terms due to elevated
inflation but weaker growth in US dollar terms due to the
expectation of further depreciation of the Sudanese pound.
- Healthcare: SDG13.07bn (US$4.93mn) in 2011 to SDG15.16bn
(US$5.14bn) in 2012; +16.0% in local currency terms and 4.2% in US
dollar terms.
Key Topics Covered:
- BMI Industry View
- Pharmaceutical Business Environment Ratings
- Rewards
- Risks
- Market Summary
- Regulatory Regime
- Industry Forecast Scenario
- Assessing The Value Of Sudan And South Sudan's Pharmaceutical
Market
- Pharmaceutical Market Forecast
- Industry Developments
- Healthcare Market Forecast
- Key Growth Factors - Macroeconomic
- Industry Risk/Reward Ratings (RRRs)
For more information visit
http://www.researchandmarkets.com/research/5a995a/sudan_and_south_su